References in periodicals archive ?
Emergent BioSolutions Inc announced today that it has completed its acquisition of raxibacumab, a fully human monoclonal antibody approved by the U.S.
M2 PHARMA-July 21, 2017-Emergent BioSolutions to acquire GlaxoSmithKline's Raxibacumab
M2 EQUITYBITES-July 21, 2017-Emergent BioSolutions to acquire GlaxoSmithKline's Raxibacumab
Moreover, Human Genome Sciences developed raxibacumab for anthrax using a part of the toxin itself, the B.
Various topics will be explored including the background to raxibacumab as a recently developed drug for treatment of inhalation anthrax; regulatory challenges and logistical challenges of implementing clinical studies during a public health emergency
The third was ABthrax (raxibacumab), a monoclonal antibody intended to provide passive immunity against anthrax toxin, a product HGS had already begun to produce for the U.S.
Revenues primarily included $19.1 million recognized from payments previously received under the ZALBIN agreement with Novartis, $13.1 million recognized from sales and deliveries of raxibacumab to the U.S.
* $315 million for 65 thousand doses of Raxibacumab (ABthrax), a treatment for anthrax, from Human Genome Sciences, Inc.;
The order for another 45,000 doses of ABthrax, or raxibacumab, is due to be delivered over a three-year period, starting late this year.
The drug, a human monoclonal antibody called raxibacumab, improved survival rates for monkeys by 64%, researchers said in an article published in the New England Journal of Medicine.
London, July 10 (ANI): An experimental drug called raxibacumab has been found to be effective in treating anthrax poisoning, say researchers.
In January 2009, HGS began delivery of 20,000 doses of ABthrax (raxibacumab) to the United States Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax.